PUBLICATION AND AUTHORSHIP. 32.01 The Company will not unreasonably withhold permission for publication of professional papers, articles, manuscripts and monographs.
PUBLICATION AND AUTHORSHIP. Notwithstanding Section 11.6(e) below, the Company will have the right to author, to publish and to retain or transfer copyright to scientific reports describing the methods and results of any or all Bionics Controlled IP that does not constitute Shared Future Intellectual Property; provided that, if the studies were conducted with the financial and/or technical support of Bionics or any of its Affiliates, such reports shall include an acknowledgment to that effect. Prior to publishing any reports or submitting any manuscripts wherein the publication could adversely affect patent rights for any Bionics Controlled IP (i.e., new inventions for which patent applications have not been filed), (i) the Company shall make the manuscripts for such reports available to Bionics or one of Bionics’ Affiliates, using reasonable efforts to provide Bionics or such Affiliate copies of such manuscripts at least thirty (30) days before submission to a journal or other publisher so that Bionics can take any steps it deems necessary to protect such Surgi-Vision IP disclosed in such manuscripts, (ii) Bionics will promptly review such manuscripts, and (iii) the Company will delay its submission to such journal or other publisher for up to one hundred eighty (180) days if Bionics, in its reasonable discretion, determines that it needs additional time to protect such Bionics Controlled IP.
PUBLICATION AND AUTHORSHIP. The Company will have the right to author, to publish and to retain or transfer copyright to scientific reports describing the methods and results of any or all Intellectual Property licensed to Bionics, provided that the manuscripts for such reports are made available to Bionics at least ninety days before publication or submission to a journal so that Bionics can take any steps deemed necessary to protect Intellectual Property disclosed in said manuscripts and articles and provided that such reports include an Acknowledgement stating that the studies were conducted with the financial and technical support of Bionics.
PUBLICATION AND AUTHORSHIP. Notwithstanding Section 9(E) above, SVI shall have the right to author, to publish and to retain or transfer copyright to scientific reports describing the methods and results of any or all Surgi-Vision IP licensed to CPI hereunder; provided that, if the studies were conducted with the financial and/or technical support of CPI or any of its Affiliates, such reports shall include an acknowledgment to that effect. Prior to publishing any reports or submitting any manuscripts wherein the publication could adversely affect patent rights for any Surgi-Vision IP (i.e., new inventions for which patent applications have not been filed), (i) SVI shall make the manuscripts for such reports available to CPI, using reasonable efforts to provide CPI copies of such manuscripts at least thirty (30) days before submission to a journal or other publisher so that CPI can take any steps it deems necessary to protect such Surgi-Vision IP disclosed in such manuscripts, (ii) CPI will promptly review such manuscripts, and (iii) SVI will delay its submission to such journal or other publisher for up to one hundred eighty (180) days if CPI, in its reasonable discretion, determines that it needs additional time to protect such Surgi-Vision IP.
PUBLICATION AND AUTHORSHIP. 11.1. The Sponsor acknowledges the importance of public disclosure/publication of information collected or generated by the Principal Investigator, under the condition that public disclosure/publication takes place under the provisions of this clause 11.
PUBLICATION AND AUTHORSHIP. ARTICLE SALARY ADMINISTRATION Salary Scales and Administration of Merit Increases Acting Pay ARTICLE TERMINATION COMPENSATION General Death Layoff Voluntary Resignation Before Retirement Retirement ARTICLE TITLE PAGE ARTICLE INFORMATION AND NOTIFICATIONS ARTICLE DURATION AND AMENDMENT OF AGREEMENT LETTER OF UNDERSTANDING APPENDIX “A” LIST OF ARBITRATORS SUPPLEMENTARY LETTERS MEMORANDUM OF AGREEMENT LEAVES OF ABSENCE ANNEX 1: COMPENSATION SYSTEM COLLECTIVE AGREEMENT between ATOMIC ENERGY OF CANADA LIMITED a Company defined in the Atomic Energy Control Act, hereinafter called ‘The Company” and THE PROFESSIONAL INSTITUTE OF THE PUBLIC SERVICE OF CANADA in respect of the PROFESSIONAL EMPLOYEES GROUP representing certain employees of the Company, hereinafter called “The Institu The Company and the Institute agree as follows:
PUBLICATION AND AUTHORSHIP. The Company will not unreasonably withhold permission or delay publication of professional papers, articles, manuscripts and monographs. The Company may suggest revisions to a publication and may withhold approval to publish. When approval for publication is withheld, for any reason, the shall be so informed in writing of the reasons, if requested by the employee. Where the Company wishes to make changes in a publication with which the author does not agree, the employee shall not be credited publicly if the employee so requests. When an employee acts as a sole or joint author or editor of a publication, the authorship or editorship shall normally be acknowledged on such publication.
PUBLICATION AND AUTHORSHIP. If NASA HRP SRE chooses to publish test and evaluation activities conducted under this MOU, NASA HRP SRE will provide a copy of the proposed publication (or, if not feasible, a summary of the proposed publication) to DGMC prior to publication. The DGMC has the right to ask NASA HRP SRE to give appropriate credit to DGMC for its contributions under this MOU, by providing written notice to NASA HRP SRE within thirty (30) days of receiving the proposed publication. The DGMC will provide NASA HRP SRE with a copy of any proposed publication that discloses or concerns any report or Test Data received from NASA HRP SRE under this MOU. APPROVED: FOR DGMC FOR NASA HRP SRE XXXXXX.XXXXXXX.J.1095 Digitally signed by XXXXXX.XXXXXXX.J.1095248230 248230 Date: 2023.06.30 17:21:20 -07'00' XXXXX XXXXXXX Digitally signed by XXXXX XXXXXXX Date: 2023.07.06 10:10:03 -05'00' Signature XXXXXXX X. XXXXXX Commander, 60th Medical Group Director, DHA Sacramento Market Signature XXXXX XXXXXXX, BS Director, Human Research Program 30 June 2023 6 July 2023
PUBLICATION AND AUTHORSHIP. The Sponsor acknowledges the importance of public disclosure/publication of information collected or generated by the Principal Investigator, under the condition that public disclosure/publication takes place under the provisions of this clause 11. Upon completion of the Clinical Trial (whether prematurely or otherwise) the Principal Investigator and Sponsor shall co-operate in producing a report of the Clinical Trial detailing the methodology, results and containing an analysis of the results and drawing appropriate conclusions. The Sponsor agrees that the Principal Investigator shall be permitted to present at symposia, national or regional professional meetings, and to publish in journals, theses or dissertations, or otherwise of its own choosing, methods and results of the Clinical Trial, subject to this clause 11 and any publication policy described in the Protocol, provided any such policy does not obstruct publication unreasonably. Upon completion of the Clinical Trial, or when the Clinical Trial data are adequate (in Sponsor's reasonable judgement), and subject to clause 11.7 hereof, the Principal Investigator may prepare the data derived from the Clinical Trial for publication or presentation. Material for public dissemination will be submitted to the Sponsor for review at least forty-five (45) days (or the time limit specified in the Protocol if longer provided it shall not exceed the time limit given under clause 11.6 sub a) prior to submission for publication, public dissemination, or review by a publication committee. The Principal Investigator agrees that all reasonable comments made by the Sponsor in relation to a proposed publication or presentation will be incorporated into the publication or presentation. During the period for review of a proposed publication referred to in clause 11.4 above, the Sponsor shall be entitled to make a reasoned request to the Principal Investigator that publication be delayed for a period of up to ninety (90) days from the date of first submission to the Sponsor in order to enable the Sponsor to take steps to protect its proprietary information and/or Intellectual Property Rights and Know How and the Principal Investigator shall not unreasonably withhold its consent to such a request; and may cause the Principal Investigator to remove from the projected publication any Sponsor Confidential Information received by Principal Investigator that are not constituted results of the Clinical Trail. If it is a multi-c...
PUBLICATION AND AUTHORSHIP. Publication and authorship between the Parties is regulated in clause 8.3. of the Protocol. Publications will be in accordance with international recognized scientific and ethical standards concerning publications and authorship, including the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, established by the International Committee of Medical Journal Editors. Copyrights concerning Publications of the Non-interventional Study remains with the authors of the Publication, regardless of any other provisions regarding intellectual property rights.
